Lincoln Pharma.

Why is Lincoln Pharmaceuticals Ltd falling/rising?

As of 07-Aug, Lincoln Pharmaceuticals Ltd's stock price is declining by 0.84% after a trend reversal, underperforming its sector by 2.33%. The stock is trading below its 50-day and 100-day moving averages, indicating a potential weakening trend.

As of 07-Aug, Lincoln Pharmaceuticals Ltd's stock price is currently falling, with a change of -5.1, representing a decrease of 0.84%. This decline follows a trend reversal after five consecutive days of gains. The stock has underperformed its sector by 2.33% today, indicating weaker performance relative to its peers. Additionally, the stock reached an intraday low of Rs 592.75, which is a drop of 2.75% from its previous levels.<BR><BR>Investor participation appears to be decreasing, as evidenced by a delivery volume of 18.84 k on 06 Aug, which has fallen by 7.02% compared to the five-day average. While the stock is trading above its 5-day, 20-day, and 200-day moving averages, it is below the 50-day and 100-day moving averages, suggesting a potential weakening trend. Overall, these factors contribute to the current decline in Lincoln Pharmaceuticals Ltd's stock price.

Which are the latest news on Lincoln Pharma.?

When is the next results date for Lincoln Pharmaceuticals Ltd?

The next results date for Lincoln Pharmaceuticals Ltd is 13 August 2026.

The next results date for Lincoln Pharmaceuticals Ltd is scheduled for 13 August 2026.

Should I buy, sell or hold Lincoln Pharmaceuticals Ltd?

How big is Lincoln Pharma.?

As of 10th June, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,271.00 Cr, with recent net sales of 671.03 Cr and a net profit of 87.89 Cr. Shareholder's funds are 671.67 Cr, and total assets amount to 797.01 Cr.

As of 10th June, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,271.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 671.03 Cr and a Net Profit of 87.89 Cr.<BR><BR>For the latest annual period, the Shareholder's Funds were 671.67 Cr, and the Total Assets amounted to 797.01 Cr.

Who are in the management team of Lincoln Pharma.?

The management team of Lincoln Pharma includes Chairman Kishorbhai M Shah, Managing Director Mahendra G Patel, and several Whole-time Directors, along with Independent Directors and a Company Secretary. They oversee the company's operations and strategic direction.

The management team of Lincoln Pharma includes the following individuals:<BR><BR>1. **Kishorbhai M Shah** - Chairman (Non-Executive)<BR>2. **Mahendra G Patel** - Managing Director<BR>3. **Hasmukhbhai I Patel** - Whole-time Director<BR>4. **Munjal Mahendrabhai Patel** - Whole-time Director<BR>5. **Aashish R Patel** - Whole-time Director<BR>6. **Anand Arvindbhai Patel** - Whole-time Director<BR>7. **Pirabhai R Suthar** - Independent Director<BR>8. **Meha Patel** - Independent Director<BR>9. **Saurin J Parikh** - Independent Director<BR>10. **Rajnikant G Patel** - Director<BR>11. **Trusha Shah** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Lincoln Pharma.?

Lincoln Pharma's peers include Ind-Swift Labs, Jagsonpal Pharma, Shukra Pharma, Syncom Formul, Fredun Pharma, Bajaj Healthcare, Fermenta Biotec, Themis Medicare, and Accent Microcell. In terms of management risk, growth, and capital structure, Lincoln Pharma is on average compared to its peers, with a 1-year return of 7.50%.

Peers: The peers of Lincoln Pharma are Ind-Swift Labs., Jagsonpal Pharma, Shukra Pharma., Syncom Formul., Fredun Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jagsonpal Pharma, Shukra Pharma., Syncom Formul., Fredun Pharma, Accent Microcell, and the rest. Average management risk is found at Ind-Swift Labs., Lincoln Pharma., Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and the rest. Below Average management risk is noted at none of the peers. Growth is excellent at Shukra Pharma. and Fredun Pharma, while Average growth is found at Jagsonpal Pharma, Lincoln Pharma., Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and the rest. Below Average growth is observed at Ind-Swift Labs., Syncom Formul., and the rest. Excellent capital structure is noted at Jagsonpal Pharma, Shukra Pharma., Syncom Formul., Lincoln Pharma., Accent Microcell, and the rest, while Below Average capital structure is found at Ind-Swift Labs., Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fredun Pharma at 211.49%, while the lowest is Jagsonpal Pharma at -13.93%. Lincoln Pharma's 1-year return of 7.50% is higher than Jagsonpal Pharma's but lower than Fredun Pharma's. Additionally, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and Syncom Formul. have negative six-month returns.

What does Lincoln Pharma. do?

Lincoln Pharmaceuticals Ltd manufactures and trades pharmaceutical products, operating in the Micro Cap market. As of March 2026, it reported net sales of 187 Cr and a net profit of 12 Cr, with a market cap of INR 1,271 Cr.

Overview:<BR>Lincoln Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and operates in the Micro Cap market segment.<BR><BR>History:<BR>The company was incorporated in January 1979 as a Partnership Firm and was converted into a Public Limited Company in January 1995. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 187 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 12 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 1,271 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 14.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.28%<BR>- Debt Equity: -0.31<BR>- Return on Equity: 11.60%<BR>- Price to Book: 1.69<BR><BR>Contact Details:<BR>- Address: Lincoln House B/H Satyam Compe, Science City Road Sola Ahmedabad Gujarat : 380060<BR>- Tel: 91-079-67778000<BR>- Email: info@lincolnpharma.com<BR>- Website: http://www.lincolnpharma.com

Are Lincoln Pharmaceuticals Ltd latest results good or bad?

Lincoln Pharmaceuticals Ltd's latest results show a significant net profit increase of 139.24% quarter-on-quarter, but a decline in net sales and operating margins raises concerns about sustainability. While the profit growth is positive, reliance on non-operating income suggests caution for investors.

Lincoln Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported a significant increase in net profit for Q1 FY26, reaching ₹27.68 crore, which is a remarkable 139.24% increase quarter-on-quarter and a 16.94% increase year-on-year. This recovery from a disappointing previous quarter is certainly a positive sign for investors.<BR><BR>However, the company's net sales of ₹154.07 crore saw an 8.39% decline compared to the previous quarter, although there was a year-on-year growth of 4.61%. This revenue volatility raises concerns about the sustainability of the profit growth, especially since the operating margin, excluding other income, fell to 13.19%, marking a multi-quarter low.<BR><BR>Additionally, a substantial portion of the profit came from other income, which constituted 43.63% of profit before tax. This reliance on non-operating income casts doubt on the core operational performance and its ability to maintain profit levels without such contributions.<BR><BR>Overall, while the profit increase is encouraging, the decline in sales and operating margins, along with the dependency on non-core income, suggest that the results are not entirely positive. Investors should be cautious and monitor the company's ability to stabilize its operational performance in the coming quarters.

Is Lincoln Pharma. technically bullish or bearish?

As of November 20, 2025, Lincoln Pharma's technical outlook is bearish, driven by bearish daily moving averages and KST indicators, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 20 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the daily moving averages, which are bearish, and the KST on both weekly and monthly time frames, which are also bearish. The monthly Bollinger Bands indicate a mildly bearish trend, while the Dow Theory shows a mildly bullish signal on the weekly but remains bearish on the monthly. Overall, the combination of these indicators suggests a bearish outlook for Lincoln Pharma.

How has been the historical performance of Lincoln Pharma.?

Lincoln Pharma has shown consistent growth in net sales and profits, with net sales increasing from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, and operating profit rising from 72.87 Cr to 123.97 Cr during the same period, despite some fluctuations in profit margins. Total assets and liabilities have also significantly increased, reflecting robust overall growth.

Answer:<BR>The historical performance of Lincoln Pharma shows a consistent growth trajectory in net sales and profit over the years.<BR><BR>Breakdown:<BR>Lincoln Pharma's net sales have increased from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, reflecting a steady upward trend. Total operating income has followed a similar pattern, rising from 366.15 Cr to 623.23 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, from 298.91 Cr in March 2019 to 521.74 Cr in March 2025. Despite this increase in expenses, operating profit (PBDIT) has shown resilience, climbing from 72.87 Cr to 123.97 Cr, although it peaked at 134.33 Cr in March 2024. Profit before tax reached 109.19 Cr in March 2025, down from 122.24 Cr in March 2024, while profit after tax was 82.35 Cr in March 2025, a decrease from 93.30 Cr in the previous year. The company's total assets have significantly increased from 389.39 Cr in March 2020 to 797.01 Cr in March 2025, indicating robust growth in its asset base. Total liabilities also rose from 389.39 Cr to 797.01 Cr over the same period. Cash flow from operating activities improved to 93.00 Cr in March 2025, up from 63.00 Cr in March 2024, contributing to a net cash inflow of 7.00 Cr in March 2025. Overall, Lincoln Pharma has demonstrated a solid performance with increasing revenues and profits, despite some fluctuations in profit margins and expenses.

Who are the top shareholders of the Lincoln Pharma.?

The top shareholders of Lincoln Pharma include promoter Munjal Mahendrabhai Patel with 13.37%, individual investors at 36.27%, and 53 foreign institutional investors holding 5.14%. The highest public shareholder is Kishor M. Shah with 2.39%.

The top shareholders of Lincoln Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Munjal Mahendrabhai Patel, owning 13.37% of the company. Additionally, individual investors hold a significant portion at 36.27%. In terms of institutional investment, 53 foreign institutional investors (FIIs) collectively hold 5.14%, while mutual funds have a minimal presence with holdings from 2 schemes at 0.0%. The highest public shareholder is Kishor M. Shah, who holds 2.39%.

Is Lincoln Pharma. overvalued or undervalued?

As of May 26, 2025, Lincoln Pharma is considered an attractive investment, assessed as undervalued with a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%, significantly lower than peers like Sun Pharma and Divi's Lab, indicating strong growth potential despite recent stock performance declines.

As of 26 May 2025, the valuation grade for Lincoln Pharma has moved from very attractive to attractive. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%. <BR><BR>In comparison to its peers, Lincoln Pharma's PE Ratio is significantly lower than Sun Pharma's 35.25 and Divi's Lab's 79.33, indicating a more favorable valuation. Additionally, while Lincoln Pharma has a PEG Ratio of 0.00, suggesting strong growth potential relative to its price, competitors like Cipla and Dr. Reddy's Labs have PEG Ratios of 0.97 and 14.54, respectively. Despite a recent decline in stock performance year-to-date, Lincoln Pharma has outperformed the Sensex over a three-year period, reinforcing its potential as an undervalued investment in the pharmaceuticals sector.

Has Lincoln Pharma. declared dividend?

Yes, Lincoln Pharmaceuticals Ltd has declared a 15% dividend, amounting to 1.5 per share, with an ex-date of September 15, 2023. While recent total returns show volatility, longer-term performance over five years has been positive, with a total return of 247.97%.

Lincoln Pharmaceuticals Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 15 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -37.95%, the dividend return was 0%, resulting in a total return of -37.95%.<BR><BR>Over the past year, the price return was -2.18%, the dividend return was 0%, leading to a total return of -2.18%.<BR><BR>In the 2-year period, the price return was 51.57%, the dividend return was 0.37%, culminating in a total return of 51.94%.<BR><BR>For the 3-year period, the price return was 98.05%, the dividend return was 1.06%, resulting in a total return of 99.11%.<BR><BR>In the last 4 years, the price return was 96.75%, the dividend return was 1.42%, leading to a total return of 98.17%.<BR><BR>Finally, over the past 5 years, the price return was 245.19%, the dividend return was 2.78%, resulting in a total return of 247.97%.<BR><BR>Overall, while Lincoln Pharmaceuticals has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last 6 months and 1 year. However, the longer-term returns show a more positive trend, especially over the 5-year period.